Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680533 | 0.80 | PTGS2 (0.49) | MAPK10PTGS1PTGS2MAPT | |
| SCHEMBL4680219 | 0.72 | PTGS2 (0.64) | PTGS1PTGS2CYP3A4ADORA1MAPT | |
| SCHEMBL14143221 | 0.70 | TUBB4A (0.39) | MAPK10CYP2D6CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL5255187 | 0.69 | HTT (0.51) | SMN1; SMN2ALDH1A1KDM4ERAB9ACYP2A13 | |
| SCHEMBL4680544 | 0.69 | PTGS2 (0.48) | MAPK10PTGS1PTGS2 | |
| Tetrahydrofuran SCHEMBL27539541 | 0.67 | IDO1 (0.38) | MAPK10KDM4ESYK | |
| SCHEMBL27827796 | 0.66 | CYP2C9 (0.54) | ADORA2ACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4680304 | 0.65 | MAPK14 (0.45) | MAPK10PTGS1PTGS2 | |
| SCHEMBL14591610 | 0.63 | PTPN1 (0.36) | MAPK10SMN1; SMN2ALDH1A1RAB9AMAPT | |
| SCHEMBL4993 | 0.63 | NOTUM (0.48) | SMN1; SMN2ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218369-B1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7169798-B2 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1218369-A4 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | GREEN JEREMY (US) | 2005-02-03 | — | — | US | disclosed |
| US-6693108-B2 | PYRIMIDINYL-GUANIDINE DERIVATIVES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-17 | — | — | US | disclosed |
| US-20030149051-A1 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTX PHARMACEUTICALS INCORPORATED | 2003-08-07 | — | — | US | disclosed |
| EP-1218369-A1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001012621-A1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149051-A1 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | MAPK1, PACSIN2, MAP3K1 | MAPK10 140/4885ADORA2A 3637/4885DCTPP1 3940/4885 |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | MAP3K2, CSNK1G2, MAP3K5 | MAPK10 139/4885ADORA2A 3356/4885DCTPP1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.